Background The relation between airway responsiveness to constrictor agents and forced expiratory volume in one second (FEV,) is important when interpreting change in airway responsiveness after an intervention. The aim of the study was to analyse the relation between FEV, as a percentage of predicted values (% predicted) and airway responsiveness between and within asthmatic subjects. Methods Results of non-specific bronchial challenge tests were pooled from two randomised crossover studies comparing the effect of a non-sedative antihistamine with placebo in 35 patients with moderate asthma. The design of the two studies was similar: the provocative concentration ofeither histamine (first study) or methacholine (second study) resulting in a 20% decrease in ventilatory capacity (PC20) was repeated at two week intervals while patients were treated with the antihistamine or placebo. The dose of inhaled corticosteroid was gradually reduced during the study. Data were analysed with PC20 as the dependent variable in a general linear model so that the influence on PC20 of inhaled corticosteroid dose, antihistamine, and choice of bronchoconstricting agent could be separated from the influence of FEV, % predicted.
(% predicted) and airway responsiveness between and within asthmatic subjects. Methods Results of non-specific bronchial challenge tests were pooled from two randomised crossover studies comparing the effect of a non-sedative antihistamine with placebo in 35 patients with moderate asthma. The design of the two studies was similar: the provocative concentration ofeither histamine (first study) or methacholine (second study) resulting in a 20% decrease in ventilatory capacity (PC20) was repeated at two week intervals while patients were treated with the antihistamine or placebo. The dose of inhaled corticosteroid was gradually reduced during the study. Data were analysed with PC20 as the dependent variable in a general linear model so that the influence on PC20 of inhaled corticosteroid dose, antihistamine, and choice of bronchoconstricting agent could be separated from the influence of FEV, % predicted.
Results The correlation coefficient between mean PC20 and mean prechallenge FEV, for each patient was 045. In the general linear model two thirds (65%) of the variation in PC20 was due to variation between subjects. One third of the within subject variation in PC20 could be explained by variation in prechallenge FEV, % predicted (a change in FEV, of 27% predicted was associated with one doubling or halving of PC20). Treatment with the antihistamine had no influence on PC20, except when histamine was used as the bronchoconstricting agent. The dose of inhaled corticosteroid had a small but significant effect. Conclusions The variation in a patient's PC20 over time (several months) is related to changes in FEV, % predicted. Variation in FEV, % predicted explains less of the variation in bronchial responsiveness between subjects where a patient specific factor, which is probably related to the pathogenesis of bronchial asthma, seems to dominate. The relation between airway calibre and bronchial responsiveness is still controversial and important when results from bronchial challenge tests are evaluated. This applies to comparisons within and between patients.
Asthmatic subjects have been examined extensively because the influence of baseline airway calibre on bronchial reactivity will act as a confounder when the effect of an intervention such as occupational exposure, drug treatment, immunotherapy, or allergen avoidance on bronchial reactivity is examined.
In this study we analysed pooled data from two randomised clinical trials comparing the effect of a non-sedative antihistamine (loratadine) with placebo in 35 patients with moderate asthma.' The patients had 12 histamine or methacholine bronchial challenge tests. We examined the relation between prechallenge forced expiratory volume in one second (FEV,) and bronchial responsiveness (the provocative concentration of constricting agent resulting in a 20% decrease in FEV, (PC20)), account being taken of the type of bronchoconstricting agent and the doses of antihistamine and inhaled steroid.
Patient and methods

PATIENTS
Fourteen men (19 to 56 years of age) and 21 women (19 to 62 years of age) (table 1) were included after they had shown (a) more than a 20% variation in peak expiratory flow (PEF) recorded during a two week period and (b) at least a 15% improvement in FEV, 10 minutes after inhalation of 0 2 mg salbutamol. They had their asthma well controlled while taking inhaled beclomethasone dipropionate 200 ,ug twice daily, with a baseline FEV, above 50% of the predicted normal value (Quanjer summary equations2). No patient had taken oral steroids for the previous two months or for longer than three months during the previous year. No patient had any other serious disease or was pregnant. All had a normal chest radiograph. Informed consent was obtained from all patients, and both studies were approved by the local ethical committee.
DESIGN
The two studies were set up primarily to investigate the effects of the antihistamine loratadine in patients with asthma.' In this paper we took the opportunity provided by the large number of measurements of bronchial responsiveness to examine possible influences on bronchial responsiveness.
Both studies had a double blind, ranMedical Department TTA 7511, State weeks-to a total dose of 50 jig twice daily for the last two weeks. For emergency treatment the patients were supplied with a salbutamol inhaler (0 1 mg/puff), which they were instructed to use when needed for immediate relief from exacerbations of their symptoms. Other antiasthmatic treatment remained constant throughout the study.
Patients kept daily records of asthma symptoms (scores for wheezing, dyspnoea, cough, sputum, and nocturnal asthma), PEF, and use of drug treatment throughout the treatment periods. At the end of every second week the patients were seen by one of the investigators, their diaries were checked, and spirometry and a measurement of non-specific bronchial responsiveness were performed. Thus bronchial challenge tests were performed 12 times for each patient.
The two studies differed in two respects. The dose of loratadine was 10 mg daily in the first study and 20 mg daily in the second. The bronchoconstricting agent was histamine in the first study and methacholine in the second. figure 1) . BDP is dosage of inhaled steroid as a quantitative covariate, and LHM is dose of antihistamine (L = loratadine) combined with type of bronchoconstricting agent (H = histamine and M = methacholine) as a qualitative factor with four categories: (a) no 
Results
The relation between bronchial responsiveness (PC20) and FEV, % predicted is shown in figure   1 . Despite individual variations in the slope of the lines there was a general tendency for increasing FEV, % predicted to be associated with increasing PC20. The slope of the regression line for each patient and the standard deviation of the slope, with the mean slope and its 95% confidence interval, are shown in figure  2 . The mean slope differed significantly from zero (p < 0-001).
The correlation coefficient (r) between mean PC20 and mean FEV, % predicted for each subject was 0 45 (p < 0.001), showing that some (r2 = 20%) of the between subject variation in bronchial reactivity could be explained by between subject variation in prechallenge FEV, % predicted. (65 %) of the variation in PC20 could be ascribed to a patient specific factor-that is, between subject variation in level of hyperresponsiveness. One third (35%) of the total variation in PC20 remained for within patient variation in responsiveness, and one third of this intraindividual variation (1 % of the total variation in bronchial reactivity) could be ascribed to within subject variation in prechallenge FEV, The interaction term between prechallenge FEVy % predicted and the patient specific factor did not reach significance (p = 0 09), which means that the variation in slope of individual patients in figures 1 and 2 can be explained by residual variation-that is, the low reproducibility of PC20 and FEV, measurements. This means that the mean slope of the regression lines in figure 1 should be considered in predicting PC20 and that individual variation in the slope of the regression lines is less important.
Inhaled steroid dosage was a significant covariate (p < 0 05), although less than 1% of the total variation in PC20 was explained by this variable. The interaction term including dose of antihistamine and type of bronchoconstricting agent was highly significant (p < 0 001), accounting for 5% of the variation in bronchial hyperresponsiveness. This factor had four categories and further analysis showed that the combination of loratadine 10 mg daily with histamine as the challenge drug differed from the three other categories and that the differences between the three other categories were insignificant, or they had no influence on PC20.
Discussion
It has been recognised since the 1960s that people with poorer lung function tend to have greater degrees of non-specific airway responsiveness.45 This relation has now been well documented in population samples6 and among cigarette smokers with chronic airflow obstruction and chronic mucus hypersecretion,78 but conflicting data have been reported on the correlation between lung function and degree of airway responsiveness among asthmatic subjects. In a study by Yan et al of 17 subjects with asthma identified on the basis of a doctor's diagnosis or intermittent wheezing or dyspnoea there was no significant correlation between lung function before challenge and PD20 FEV,.9
Rubenfeld and Pain observed no significant correlation between methacholine airway responsiveness and prechallenge specific airway conductance among 11 asthmatic volunteers with a wide range of prechallenge conductance,10 and Chung et al concluded that bronchial hyperreactivity in asthmatic subjects is unlikely to be a direct consequence of a low starting airway calibre." 12 In contrast, Cockcroft et al observed a significant direct correlation between prechallenge FEV, and PC20 FEV, (r = 0 49) among 156 patients with well controlled atopic asthma,'3 and a smaller study of 15 asthmatic subjects gave a similar correlation of 0 42.'4 In our study we found a correlation coefficient of 0-45.
In most studies bronchial reactivity has been measured on only a single occasion in each patient, and consequently investigators could analyse only between subject variation in bronchial responsiveness and ventilatory capacity. In a more recent longitudinal study of 20 asthmatic subjects reactivity to methacholine was measured every two to three weeks for 12 to 18 months. 5 The aim of this study and therefore the statistical analyses differed from that of our study, however. The subjects' overall reactivity (median PD20) was related only to average variation in PEF, and the temporal relation between trends in PD20 and PEF and FEV, within subjects was based on subjective interpretation of charted serial data in individual patients. The statistical analysis ofthe data was confined to Spearman's p, which did not take into account the possibility that treatment may have modified the degree of reactivity.
In our study non-specific airway responsiveness was measured 12 times in each patient at intervals of two (or more) weeks, which enabled us to analyse the within patient relation between prechallenge FEV1 % predicted and bronchial reactivity (PC20). The analysis was performed in a general linear model in which the influence of an inhaled corticosteroid, an antihistamine, and a choice of bronchoconstricting agent on bronchial hyperresponsiveness could be separated from the influence of FEV, % predicted.
Histamine and methacholine produce bronchoconstriction by different mechanisms, and a person's sensitivity to these different agents may vary. None the less, among asthmatic subjects a high correlation has been observed between methacholine and histamine responsiveness. 6 In our general linear model splitting the LHM term into separate categories for bronchial challenge with histamine and challenge with methacholine did not improve the explanatory power of the model, and thus pooling of data from two studies differing with regard to bronchoconstricting agent was considered to be acceptable. Only a modest part of the variation in bronchial hyperresponsiveness could be explained by the effect of drugs (loratadine and inhaled corticosteroids). '7 18 Two thirds (65%) of the total variation in bronchial responsiveness could be ascribed to between subject variation, leaving one third of the variation to be explained by within subject variation. Only 16% of the total variation in non-specific airway responsiveness was not accounted for by the explanatory variables of the model.
The analysis showed that prechallenge FEV1 % predicted was a strong explanatory variable for between subject and especially within subject variation in bronchial responsiveness. The close within subject relation between prechallenge level of pulmonary function and degree of responsiveness to the bronchoconstricting agents may be explained in part at least by geometric factors.'920 Because the resistance of a tube is inversely related to its radius to the fourth power, a given degree of circumferential shortening of bronchial smooth muscle will cause a greater increase in airway resistance in a narrower airway than in a wider airway.
In The results of an analysis of the relation between bronchial responsiveness to nonspecific bronchoconstrictors and airway calibre will depend on the selection of subjects for the study. All our patients had asthma with documented reversible airway obstruction and most were atopic and had not smoked cigarettes. Any admixture of normal subjects or patients who smoke and have chronic obstructive lung disease would be likely to strengthen the relation between airway responsiveness and FEVI.8
In conclusion, we found a large variation in bronchial responsiveness to histamine or methacholine between asthmatic subjects that was only moderately related to prechallenge FEV, % predicted. Variation in FEV, % predicted explained one third of the variation in the response of an individual patient, however, when bronchial challenge was repeated.
The effect of an inhaled corticosteroid was small, and treatment with an antihistamine was important only when histamine was used as the bronchoconstricting agent.
The practical clinical aspect of our findings is that airway responsiveness cannot be predicted with any precision from an asthmatic patient's FEV, % predicted. Once bronchial reactivity has been determined, however, subsequent monitoring of bronchial responsiveness partly mirrors changes in FEVI, which can be monitored easily.
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